[
  {
    "ts": null,
    "headline": "AbbVie price target lowered to $233 from $248 at BofA",
    "summary": "BofA lowered the firm’s price target on AbbVie (ABBV) to $233 from $248 and keeps a Neutral rating on the shares. The firm, which sees “a relatively clean setup” for growth at the high end of the peer group being balanced by a premium multiple and limited late-stage pipeline catalysts, is shifting its valuation basis to its FY27 estimates.Claim 50% Off TipRanks Premium and Invest with Confidence Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper",
    "url": "https://finnhub.io/api/news?id=4bb4a615478d6042407644d40aa5516380574da33f4e15d2b62831196c9f2992",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765895707,
      "headline": "AbbVie price target lowered to $233 from $248 at BofA",
      "id": 137806079,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "BofA lowered the firm’s price target on AbbVie (ABBV) to $233 from $248 and keeps a Neutral rating on the shares. The firm, which sees “a relatively clean setup” for growth at the high end of the peer group being balanced by a premium multiple and limited late-stage pipeline catalysts, is shifting its valuation basis to its FY27 estimates.Claim 50% Off TipRanks Premium and Invest with Confidence Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper",
      "url": "https://finnhub.io/api/news?id=4bb4a615478d6042407644d40aa5516380574da33f4e15d2b62831196c9f2992"
    }
  },
  {
    "ts": null,
    "headline": "Cradle AI-powered protein engineering platform serving six of top 25 pharma leaders",
    "summary": "Cradle, an enterprise-grade AI software platform, today announced a series of milestones that signal a new phase of growth. The company saw rapid adoption across the pharma industry, with Cradle now running 50+ projects and powering drug discovery programs for six of the top 25 big pharma companies, including Johnson & Johnson, Abbvie, and Novo Nordisk. To continue expanding product capabilities and meet surging global demand, the company has doubled headcount across all departments and expanded",
    "url": "https://finnhub.io/api/news?id=11ac9fc5d4be06d9c08abf1ee99c77e2dd30c8183a6de046f349850410397782",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765890000,
      "headline": "Cradle AI-powered protein engineering platform serving six of top 25 pharma leaders",
      "id": 137806042,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "Cradle, an enterprise-grade AI software platform, today announced a series of milestones that signal a new phase of growth. The company saw rapid adoption across the pharma industry, with Cradle now running 50+ projects and powering drug discovery programs for six of the top 25 big pharma companies, including Johnson & Johnson, Abbvie, and Novo Nordisk. To continue expanding product capabilities and meet surging global demand, the company has doubled headcount across all departments and expanded",
      "url": "https://finnhub.io/api/news?id=11ac9fc5d4be06d9c08abf1ee99c77e2dd30c8183a6de046f349850410397782"
    }
  }
]